BAC Water with CJC-1295 and Ipamorelin: Reconstitution Protocols for GH Research Peptides
Research Notice: This article covers research topics relevant to BAC Water — available from Palmetto Peptides for laboratory use only.
DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research or laboratory use. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.
BAC Water with CJC-1295 and Ipamorelin: Reconstitution Protocols for GH Research Peptides
Last Updated: May 18, 2026 | Reading Time: Approximately 11 minutes | Author: Palmetto Peptides Research Team
Quick Answer
CJC-1295 and ipamorelin are two structurally distinct growth hormone-related research peptides that are frequently studied together because they act through complementary pathways in the GH secretory axis. Both compounds are best reconstituted using bacteriostatic water (BAC water), which maintains sterility across multi-dose research protocols. CJC-1295 is most commonly prepared at 1.0 to 2.0 mg/mL; ipamorelin is typically reconstituted at 2.0 to 5.0 mg/mL, though specific concentrations depend on the research protocol and dosing scheme under investigation.
Introduction: Two Peptides, Two Mechanisms, One Research Category
Few pairings in the growth hormone research space have attracted as much sustained scientific interest as CJC-1295 and ipamorelin. These two peptides represent different branches of the GH secretory regulatory tree: CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that acts on pituitary somatotroph cells via the GHRH receptor, while ipamorelin is a growth hormone secretagogue (GHS) that acts via the ghrelin receptor (GHS-R1a). Together, they stimulate GH release through distinct but synergistic signaling pathways in animal models.
Before researchers can work with either compound in the laboratory, they must reconstitute the lyophilized peptide powders into sterile, stable solutions suitable for their experimental delivery route. The choice of reconstitution vehicle matters — it affects how long the preparation remains usable, whether contamination risk is adequately managed in multi-dose protocols, and whether any vehicle components interfere with the assays or biological systems under study. This guide covers the specific reconstitution requirements for both CJC-1295 and ipamorelin using BAC water, including critical differences between CJC-1295 with and without DAC (Drug Affinity Complex).
CJC-1295: Understanding the DAC and No-DAC Distinction
What Is CJC-1295 Without DAC?
CJC-1295 without DAC — sometimes referred to as Modified GRF (1-29) or Mod GRF 1-29 — is a 29-amino-acid synthetic analog of the first 29 residues of endogenous growth hormone-releasing hormone. It is modified at four positions (Ala2, Gln8, Ala15, Leu27 are substituted with D-Ala, Gln(OH), Ala, D-Ala respectively in various vendor formulations) to improve stability against dipeptidyl peptidase-4 (DPP-4), the protease that rapidly degrades native GHRH in plasma. The result is a peptide with a significantly extended half-life compared to native GHRH, but still substantially shorter than CJC-1295 with DAC.
In preclinical research, CJC-1295 without DAC produces a pulsatile pattern of GH secretion in animal models, more closely mimicking the natural episodic GH release pattern. This characteristic is specifically valued by researchers studying GH pulse dynamics and the downstream effects of pulsatile versus continuous GH exposure on IGF-1 production, body composition, and metabolic markers in rodent models.
What Is CJC-1295 With DAC?
CJC-1295 with DAC adds a Drug Affinity Complex — a lysine-maleimido-propionic acid linker — to the C-terminal end of the peptide. This modification allows the peptide to form a covalent bond with serum albumin after reconstitution and administration in research models, dramatically extending its half-life from hours (without DAC) to approximately one week (with DAC) in animal models. This extended half-life produces a more prolonged elevation of circulating GH levels.
The DAC modification has implications for reconstitution: CJC-1295 with DAC is a larger, more complex molecule (approximately 3647 Da versus approximately 3367 Da for the no-DAC form). It dissolves similarly well in BAC water, but researchers should be aware that the albumin-binding maleimide group in the DAC linker can react with free thiol groups (cysteines) in proteins and buffers. This is relevant if the reconstituted CJC-1295 with DAC will be used in cell culture experiments containing cysteine-rich media supplements — the DAC linker may form adducts with media components.
Reconstitution Differences Between DAC and No-DAC Forms
| Property | CJC-1295 Without DAC | CJC-1295 With DAC |
|---|---|---|
| Molecular weight (approx.) | ~3367 Da | ~3647 Da |
| Aqueous solubility | Good in BAC water | Good in BAC water |
| Albumin binding reactivity | None | Yes — DAC linker reacts with albumin thiol |
| Preclinical half-life estimate | 30 min to 2 hours in rodent models | Approximately 5-7 days in animal models |
| GH secretion pattern in research models | Pulsatile | Sustained elevation |
| Recommended stock concentration | 1.0 to 2.0 mg/mL | 1.0 to 2.0 mg/mL |
| Special reconstitution considerations | Standard BAC water protocol | Avoid thiol-containing buffers; use promptly |
Ipamorelin: The Selective GH Secretagogue
Ipamorelin's Molecular Profile
Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) with a molecular weight of approximately 711 Da. It is classified as a growth hormone secretagogue (GHS) and acts as a selective agonist at the ghrelin receptor (GHS-R1a). What distinguishes ipamorelin from earlier GH secretagogues in research settings is its selectivity profile: it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels in animal model studies, making it a useful tool for research focused specifically on the GH/IGF-1 axis without confounding secretion of other pituitary hormones.
Ipamorelin's relatively small molecular weight and predominantly hydrophilic character make it among the easiest peptides to reconstitute in aqueous vehicles including BAC water. Dissolution is rapid and complete at standard laboratory temperatures.
The Synergy Rationale in Research Models
The reason CJC-1295 and ipamorelin are so frequently co-studied is mechanistic complementarity. CJC-1295 acts via the GHRH pathway (stimulating GH release via Gs-coupled adenylyl cyclase signaling), while ipamorelin acts via the ghrelin receptor (stimulating GH release through a distinct Gq-coupled pathway and also through reduction of somatostatin tone). When administered together in animal models, the two pathways produce additive or synergistic GH release. Research using this combination allows investigators to study robust GH secretory responses in models where single-agent stimulation produces more modest effects, and to characterize downstream metabolic, anabolic, and neuroendocrine effects of combined GHRH/GHS receptor activation.
BAC Water as Reconstitution Vehicle for Both Peptides
Why BAC Water Is Preferred
Both CJC-1295 and ipamorelin are typically studied in multi-dose research protocols — animal model studies may involve daily or twice-daily administration over periods of weeks. This research design requires a reconstituted peptide preparation that remains sterile and chemically stable across many days of vial access. Bacteriostatic water's 0.9% benzyl alcohol content prevents bacterial proliferation between accesses, making it far safer for multi-dose protocols than sterile water for injection, which should be used immediately and discarded after single use.
Neither CJC-1295 nor ipamorelin undergoes chemical reactions with benzyl alcohol at the concentrations present in BAC water under normal storage conditions. The preservative does not displace the peptide's amino acid residues or cleave peptide bonds under mildly acidic to neutral pH conditions. For a broader overview of BAC water's properties and uses across peptide research, see our BAC water complete guide.
Comparison of Reconstitution Vehicles for GH Research Peptides
| Vehicle | Multi-Dose Suitability | Impact on CJC-1295 | Impact on Ipamorelin |
|---|---|---|---|
| BAC Water (0.9% benzyl alcohol) | Excellent | Compatible; no chemical interactions | Compatible; no chemical interactions |
| Sterile Water for Injection | Single-use only | Chemically compatible; discard unused | Chemically compatible; discard unused |
| Normal Saline (0.9% NaCl) | Single-use only | Ionic strength may affect some assays | Compatible; ionic strength consideration |
| PBS pH 7.4 | Single-use only | Compatible; good pH stability | Compatible; watch DAC thiol reactivity |
| Acetic acid (0.1%) | Single-use only | Not recommended; promotes degradation | Not recommended for ipamorelin |
Step-by-Step Reconstitution Protocols
Protocol for CJC-1295 (Both DAC and No-DAC Forms)
Allow the lyophilized CJC-1295 vial and BAC water to reach room temperature. Work in a clean environment — a laminar flow biosafety cabinet is preferred. Swab the septum of the CJC-1295 vial with a fresh alcohol swab. Draw the calculated volume of BAC water into a 1 mL sterile syringe. Insert the needle into the vial at an angle and add the BAC water by running it slowly down the glass wall of the vial — avoid directing the stream forcefully onto the lyophilized peptide cake.
CJC-1295 may require slightly longer dissolution time than shorter peptides due to its 29-amino-acid length and higher molecular weight. Gentle swirling for two to five minutes should achieve complete dissolution. Do not use a vortex mixer or shake vigorously, as this risks peptide denaturation and foaming. Once dissolved, the solution should be clear and colorless.
For the DAC form specifically: reconstitute and use within the planned study period. Avoid storing the reconstituted DAC form in contact with thiol-containing substances (including DTT, beta-mercaptoethanol, or media containing high cysteine concentrations) as the maleimide linker may react irreversibly with free thiols.
Protocol for Ipamorelin
Ipamorelin reconstitution follows the standard BAC water protocol and is among the most straightforward of common research peptide reconstitutions due to the compound's small size (711 Da) and high aqueous solubility. Allow vial and BAC water to reach room temperature. Swab the septum, draw the calculated BAC water volume, and add slowly down the vial wall. Ipamorelin typically dissolves within 60 seconds of gentle swirling. The resulting solution is clear and colorless. Transfer promptly to refrigerated storage.
Concentration Calculations
Target stock concentrations for CJC-1295 and ipamorelin are protocol-dependent, but common reference ranges are as follows. For CJC-1295 (either form): stock solutions of 1.0 to 2.0 mg/mL in BAC water are most common in published research, providing sufficient concentration for typical rodent model dosing while maintaining acceptable solution volumes. For ipamorelin: stock solutions of 2.0 to 5.0 mg/mL are commonly reported, reflecting ipamorelin's smaller molecular weight and the correspondingly higher molar concentrations achievable at given mass concentrations.
To calculate the BAC water volume needed: divide the total peptide mass in the vial (mg) by the target concentration (mg/mL). For example, a 2 mg CJC-1295 vial reconstituted to 1.0 mg/mL requires 2.0 mL of BAC water. A 5 mg ipamorelin vial reconstituted to 2.5 mg/mL requires 2.0 mL of BAC water. For a detailed walkthrough of dilution calculations, concentration conversions, and dose-volume math, see our guide on BAC water concentration calculations for peptide research.
Mixing Considerations When Combining CJC-1295 and Ipamorelin
Can They Be Reconstituted Together?
Researchers studying the combination of CJC-1295 and ipamorelin may wonder whether the two peptides can be reconstituted in the same vial or must be kept separate until point of use. In practice, both compounds are chemically compatible in aqueous solution at the concentrations typically used in research. Neither CJC-1295 nor ipamorelin contains reactive groups (such as free cysteines) that would form covalent bonds with the other compound. They can be combined in the same solution if the experimental protocol calls for simultaneous delivery.
However, combining them in a single vial does add complexity: if the concentrations need to differ (which is common, since optimal research doses of the two compounds may not have the same ratio for all experimental endpoints), maintaining precise concentration ratios requires careful calculation. Many researchers prefer to reconstitute each peptide separately and combine the appropriate volumes immediately before use, preserving flexibility in dosing ratios across the study.
If using CJC-1295 with DAC in combination with ipamorelin, be particularly mindful that the DAC linker in CJC-1295 does not react with ipamorelin's amino groups under normal aqueous conditions — this is not a concern. The DAC reactivity is specific to thiol groups (-SH), which ipamorelin does not contain.
Stability and Storage for Both Peptides
CJC-1295 Stability in BAC Water
Reconstituted CJC-1295 in BAC water should be stored at 2 to 8 degrees Celsius, protected from light. Under these conditions, CJC-1295 (no-DAC form) is generally stable for 28 to 30 days. The DAC form may have slightly different stability due to the reactive maleimide group — researchers should use the DAC form within the same timeframe and ensure the solution is not exposed to thiol-containing environments. Lyophilized CJC-1295 powder should be stored at -20 degrees Celsius or below before reconstitution. For long-term stock management, consider aliquoting the reconstituted solution into single-use volumes and storing at -20 to -80 degrees Celsius.
Ipamorelin Stability in BAC Water
Ipamorelin's small size and robust chemical stability make it one of the more forgiving research peptides in terms of storage. Reconstituted in BAC water and stored at 2 to 8 degrees Celsius, ipamorelin is generally stable for 28 to 30 days. The peptide does not contain photo-sensitive residues and does not have reactive groups that would create specific chemical stability concerns beyond the standard peptide hydrolysis and oxidation mechanisms that apply to all peptide solutions. For comprehensive storage guidance, see our article on BAC water storage and shelf life for research labs.
Contamination Prevention in GH Research Peptide Protocols
Growth hormone research protocols frequently require daily or twice-daily access to reconstituted peptide vials over weeks-long study periods. This high frequency of vial access makes contamination prevention especially critical. Each insertion of a needle through the rubber septum carries a small but real risk of introducing microorganisms. BAC water's bacteriostatic agent reduces the proliferation risk between accesses, but researchers should still use a new sterile needle for every withdrawal, swab the septum before each access, and inspect the solution visually for cloudiness or particulate matter at each use. For detailed contamination prevention protocols, see our guide on BAC water contamination prevention for research labs.
Research Applications: What CJC-1295 and Ipamorelin Studies Examine
Published preclinical research using CJC-1295 and ipamorelin has examined a broad range of biological outcomes relevant to the GH/IGF-1 axis. Studies in rodent models have measured circulating GH pulse amplitude and frequency, plasma IGF-1 levels, lean body mass and fat mass changes, bone density parameters, metabolic rate indicators, and cognitive function markers over various treatment durations. The combination protocol allows researchers to activate both branches of the GH secretory system simultaneously, producing more robust GH secretory responses than either compound alone in most animal model contexts.
For researchers building a peptide research program that includes GH-related compounds, Palmetto Peptides offers both CJC-1295 and ipamorelin for laboratory use, along with the BAC water needed for reconstitution. For comparison with other BAC water-reconstituted peptide systems, our article on BAC water vs. sterile water for peptide reconstitution provides useful context on vehicle selection across research programs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC for reconstitution purposes?
Both forms reconstitute similarly in BAC water and achieve comparable concentrations. The key difference is that CJC-1295 with DAC contains a maleimide-based Drug Affinity Complex linker that reacts with serum albumin after administration, extending the compound's half-life in animal models to approximately one week. For reconstitution, this means the DAC form should not be stored or used in the presence of thiol-containing buffers (DTT, beta-mercaptoethanol, cysteine-rich media) as the maleimide group may react irreversibly. The no-DAC form does not have this concern.
Can CJC-1295 and ipamorelin be combined in the same vial?
Yes, both compounds are chemically compatible in aqueous solution at typical research concentrations. Neither contains reactive groups that would form covalent bonds with the other. However, many researchers prefer to reconstitute them separately to maintain dosing flexibility throughout the study. If combined, calculate concentrations carefully to achieve the desired ratio for your specific protocol.
What concentration should I use for ipamorelin in research protocols?
Stock concentrations of ipamorelin in BAC water typically range from 2.0 to 5.0 mg/mL in published preclinical research. The optimal concentration for your specific protocol depends on the dosing requirements of your animal model, the delivery route, and the experimental endpoints. Ipamorelin's small molecular weight (711 Da) means that a 5 mg/mL solution provides a much higher molar concentration than the same mass per volume of a larger peptide.
How does the GHRH and ghrelin receptor synergy affect research study design?
The complementary mechanisms of CJC-1295 (GHRH receptor) and ipamorelin (ghrelin receptor/GHS-R1a) allow researchers to study additive or synergistic GH secretory responses in animal models. This is important for study design because it affects the expected magnitude of GH response, the timing of GH measurement post-administration, and the downstream IGF-1 responses measured over the study period. Researchers should consider both compounds' pharmacokinetics in their model system when designing the timing of administration and outcome measurement.
Why is BAC water preferred over sterile water for multi-dose GH peptide protocols?
Multi-dose protocols require accessing the same vial repeatedly over days to weeks. Sterile water for injection contains no preservative, meaning any microorganism introduced during needle access can proliferate freely in the solution before the next use. BAC water's benzyl alcohol prevents this microbial proliferation, maintaining microbiological quality of the preparation between accesses. This is critical for research data quality and reproducibility in longitudinal animal model studies.
How do I store reconstituted CJC-1295 and ipamorelin?
Both compounds should be stored at 2 to 8 degrees Celsius in light-protected containers after reconstitution in BAC water. Under these conditions, both are generally stable for 28 to 30 days. For longer storage, prepare aliquots and freeze at -20 to -80 degrees Celsius, thawing each aliquot once for use. Avoid repeated freeze-thaw cycles, which promote peptide aggregation and degradation.
Is there any concern about benzyl alcohol affecting GH secretion assays?
When BAC water-reconstituted peptides are diluted to working concentrations in animal studies, benzyl alcohol is typically diluted to levels well below concentrations known to affect neuroendocrine function. However, for in vitro pituitary cell or hypothalamic cell studies, researchers should verify that the final benzyl alcohol concentration in culture wells is not cytotoxic or pharmacologically active in their specific cell model. A benzyl alcohol-only control can help characterize any vehicle effects independent of the peptide compounds.
Peer-Reviewed Citations
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Bowers CY, Momany FA, Reynolds GA, Hong A. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Endocrinology. 1984;114(5):1537-1545.
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.
- Johansen PB, Segev Y, Landau D, Flyvbjerg A, Gronbaek H. "Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue." Experimental Diabesity Research. 2003;4(2):73-81.
- Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Annals of Internal Medicine. 2008;149(9):601-611.
- Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308.
Final Disclaimer: All compounds discussed are research chemicals not approved by the FDA for human or veterinary use. All content here is for scientific and educational reference only. Palmetto Peptides sells these products exclusively for in vitro and preclinical laboratory research.
Authored by the Palmetto Peptides Research Team | Last Updated: May 18, 2026